Clinical Trials Logo

Filter by:
NCT ID: NCT05190887 Recruiting - Expectations Clinical Trials

What do Patients Expect After Scaphoid Fractures?

Start date: April 1, 2021
Phase:
Study type: Observational

This study will assess patients expectations pre-op and assess their views on their outcome at one year follow up

NCT ID: NCT05162521 Recruiting - Fracture Clinical Trials

The Impact of Lower Limb Fractures on Body Mass Index (BMI)

Start date: April 1, 2021
Phase:
Study type: Observational

The study will prospectively follow patients with lower limb fractures to assess changes in weight after injury

NCT ID: NCT04979195 Completed - Clinical trials for COVID-19 Positive Patients With Acute Kidney Injury

Acute Kidney Injury Among COVID-19 Positive Patients

AKI-COVID-19
Start date: March 1, 2020
Phase:
Study type: Observational [Patient Registry]

In Kuwait, the total number of COVID-19 confirmed cases exceeds 5000 patients. Risk factors of possible risk factors of confirmed COVID-19 infection that developed major organ dysfunction are not yet identified among patients in Kuwait. we aimed to describe the clinical characteristics of hospitalized symptomatic COVID-19 positive patients, assess possible risk factors of confirmed COVID-19 infection who developed major organ dysfunction, determine risk factors for renal dysfunction and their outcome and assess the response of critically ill patients to different therapeutic modalities.

NCT ID: NCT04964908 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia

CREEK
Start date: November 7, 2021
Phase:
Study type: Observational

A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions.

NCT ID: NCT04943523 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Krill Oil and Muscle Weakness in Type 2 Diabetes

KRIMD
Start date: January 2022
Phase: N/A
Study type: Interventional

The age-related loss of muscle mass and function, sarcopenia, has several deleterious effects, such as a reduction in the quality of life and an increase in the incidence of falls, often leading to hospitalisation. The prevalence of sarcopenia is unclear but is estimated to be between 4.6 and 7.9% and the loss of skeletal muscle mass and function is accelerated in people with type 2 diabetes. With the percentage of older people and the percentage of people with type 2 diabetes predicted to rise in coming years it is crucial to develop therapies to increase muscle mass and function. Alterations in nutrition have also been suggested to be of therapeutic use in sarcopenia. Epidemiological data showed that the consumption of fatty fish is positively associated with muscle function in older population, indicating a potential role for long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) in increasing muscle mass and function in older people. The aim of the current study, therefore, is to determine the effects of krill oil supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.

NCT ID: NCT04907955 Completed - Visual Impairment Clinical Trials

Visual Performance Following Implantation of Presbyopia Correcting IOLs

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The purpose of the current study was to compare the visual performance after bilateral implantation of the Panoptix IOL , or the AT LISA IOL or Tecnis Symfony IOL . The focus was on intermediate vision, defocus curves, and contrast sensitivity.

NCT ID: NCT04904887 Recruiting - Presbyopia Clinical Trials

Clinical Outcomes With a New Monofocal IOL Enhanced for Intermediate Vision

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

phacoemulsification with insertion of EYHANCE IOL to improve near and intermediate vision

NCT ID: NCT04904874 Recruiting - Clinical trials for Meibomian Gland Dysfunction

Intense Pulsed Light Therapy in Meibomian Gland Dysfunction

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

to evaluate the effect of intense pulsed light on resistant patients with Meibomian gland dysfunction

NCT ID: NCT04898374 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Start date: May 1, 2021
Phase: Phase 3
Study type: Interventional

The standard of care for locally advanced nasopharyngeal carcinoma is radical chemoradiation(CRT).Recent advances in radiation techniques and supportive measures resulted in improvemnent of locoregional control and quality of life.However distant failure is still the main challenging reason of poor survival Addition of systemic therapy to concurrent CRT is widely used and accepted as an option to reduce these failures ,however selection of chemotherapy regimen and timing in relation to CRT is controversial. Doublet and triplet chemotherapy regimens using cisplatin and 5FU are throughly investigated in this setting.Inspite of significant improvement in disease free survival and overall survival they were poorly tolerated.Hence,minority of patients in the daily practice could tolerate those studied regimens as propsed. Recently, in multicenter randomized trial, Zhang and his group investigated gemcitabine and cisplatin as induction chemotherapy (ICT) added to CRT.It showed improvement in recurrence free survival and overall survival.More importantly 96.7% of the experimental arm completed the treatment protocol. This was further confirmed by an updated network of meta analysis by Bongiovanni et al.Again the question of "when" is still valid.Our proposal is to compare tolerable regimen in induction versus adjuvant settings.

NCT ID: NCT04846244 Recruiting - Clinical trials for Radiographic Axial Spondylarthritis (r-axSpA)

A Study of the Change in Early and Sustained Pain Control in Radiographic Axial Spondylarthritis in Adult Participants Receiving Upadacitinib

UPSTAND
Start date: April 30, 2021
Phase:
Study type: Observational

Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to distinguish from other causes of chronic back pain (CBP). Many participants report persistent pain, including back pain, which impacts disease activity and quality of life including creating burdens such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. Despite this, there is a lack of detailed data and knowledge on pain in radiographic-axial spondyloarthritis (r-axSpA), including pain types, how it is localized, and how these different facets of pain are impacted by treatment. This study will assess the real-world effectiveness of upadacitinib on early and sustained pain control, and the association between pain and clinical/patient-reported outcomes in radiographic axSpA participants. Upadacitinib is being developed for the treatment of r-axSpA. Approximately 877 adult participants with activer-axSpA will be enrolled across approximately 19 countries in Europe, North America, South America, and Asia-Pacific. Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. The overall duration of the study is approximately 30 months. There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.